Sonoma Pharma Q1 Revenue Jumps 60% to $6.4M, Nears Breakeven
SNOA sits 36% above its 52-week low of $0.85.
Summary
Sonoma Pharmaceuticals reported Q1 FY2027 revenue of $6.4 million, a 60% year-over-year increase driven by a 141% surge in US sales from over-the-counter products and expanded distribution. Net loss narrowed to $330,000, an 88% improvement per share, with gross margin expanding to 40% as operating expenses held flat. European revenue grew 34% on demand and favorable FX. The company added distributors in Taiwan, Vietnam, and the US, and cited new FDA clearances supporting commercial growth. This follows the 10-K filed in June highlighting cash burn concerns and the recent ATM expansion to $3.6 million. The near-breakeven result and strong top-line growth mark a significant inflection, though the low market cap and Nasdaq delisting risk flagged in the 10-Q remain key overhangs. Additionally, the company achieved positive EBITDA for the first time with record quarterly revenue.
At the time of this announcement, SNOA was trading at $1.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.4M. The 52-week trading range was $0.85 to $6.92. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.